Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

by Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley
Published 2018-05-01

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.

by Mark Yarchoan, Aditya A Mohan, Lauren Dennison, Teena Vithayathil, Amanda Ruggieri, Gregory B Lesinski, Todd D Armstrong, Nilofer S Azad, Elizabeth M Jaffee
Published 2019-01-01

Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma

by Angela Y. Jia, Amol Narang, Bashar Safar, Atif Zaheer, Adrian Murphy, Nilofer S. Azad, Susan Gearhart, Sandy Fang, Jonathan Efron, Tam Warczynski, Amy Hacker-Prietz, Jeffrey Meyer
Published 2019-08-01

Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

by Joeri A. J. Douma, Laurien M. Buffart, Ramy Sedhom, Mariette Labots, Willemien C. Menke-van der Houven van Oordt, Mikkjal Skardhamar, Anthony De Felice, Esther Lee, Divya Dharmaraj, Nilofer S. Azad, Michael A. Carducci, Henk M. W. Verheul
Published 2021-05-01

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or m...

by Marina Baretti, Enusha Karunasena, Marianna Zahurak, Rosalind Walker, Yang Zhao, Thomas R. Pisanic 2nd, Tza‐Huei Wang, Tim F. Greten, Austin G. Duffy, Elske Gootjes, Gerrit Meijer, Henk M.W. Verheul, Nita Ahuja, James G. Herman, Nilofer S. Azad
Published 2021-05-01

Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal...

by Jessica A. Smith, Aaron T. Wild, Aatur Singhi, Siva P. Raman, Haoming Qiu, Rachit Kumar, Amy Hacker-Prietz, Ralph H. Hruban, Ihab R. Kamel, Jonathan Efron, Elizabeth C. Wick, Nilofer S. Azad, Luis A. Diaz, Yi Le, Elwood P. Armour, Susan L. Gearhart, Joseph M. Herman
Published 2012-01-01

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

by Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad
Published 2020-02-01

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic

by Angela Y. Jia MD, PhD, Aleksandra Popovic BS, Aditya A. Mohan BS, Jane Zorzi BS, Paige Griffith MSN, AG-ACNP, BSN, Amy K. Kim MD, Robert A. Anders MD, PhD, Richard A. Burkhart MD, Kelly Lafaro MD, MPH, Christos Georgiades MD, PhD, Nilofer S. Azad MD, Robert P. Liddell MD, Marina Baretti MD, Ihab R. Kamel MD, PhD, Amol Narang MD, Mark Yarchoan MD, Jeffrey Meyer MD
Published 2021-04-01